``We're engaging physicians and patients with the possibilities of the genetic world.``

Anne Wojcicki CEO | 23andMe

Improving consumer health is in our DNA.

23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome.

23andMe offers two saliva-based, over-the-counter genotyping services: Health + Ancestry Service or an Ancestry Service-only option. Over 125 genetic reports are returned directly to customers through a private and secure account online. The analysis includes information on genetic health risk*, carrier status*, ancestry, wellness and genetic traits that enables consumers to learn about genetics and to engage in conversations about their health and family history with their healthcare provider.

23andMe is the first and only company authorized by the FDA to provide personal Health Predispositions reports and Carrier Status reports directly to consumers. As new reports receive market authorization from the FDA and as genomics knowledge continues to advance, eligible customers will receive additional genetic reports.

Accelerating research.
Making an impact.

Our innovative research platform has changed the research paradigm by enabling active consumer participation. 23andMe has millions of customers worldwide, with ~80% of customers consenting to participate in research. It is currently the world’s largest consented, re-contactable database for genetic research. Our research has shed light on a host of new genetic variations associated with certain diseases while fostering a better understanding of consumer comprehension of direct-to-consumer genetic test results.

Research is conducted independently, in collaboration with third parties, including academic institutions such as the University of Chicago, the MRC Epidemiology Unit, the University of Cambridge, Stanford University and the Broad Institute of MIT and Harvard, companies such as Pfizer and Genentech, and nonprofits such as the Lupus Research Institute, The Michael J. Fox Foundation and the National Parkinson Foundation.

Developing breakthrough medicines.

The 23andMe Therapeutics division was created in April 2015 and is led by Dr. Richard Scheller. The Therapeutics team is committed to discovering and developing novel therapies that can offer benefits for patients. This dedicated research and drug development group identifies novel targets using the 23andMe genetic database, generates lead compounds to these targets and performs preclinical research to support future clinical development. The team currently has research programs across several therapeutic areas, including including skin, liver and cardiovascular diseases, oncology and immunological disorders (including asthma).

Personal, private & secure.

At 23andMe, our customers are in control of their genetic information. At their discretion, they can authorize 23andMe to share their data with family members, healthcare professionals or other institutions conducting disease research. We make every effort to ensure they have complete control over access to their information.

We will not share your patients’ individual data without their explicit consent, and we do not provide information to law enforcement unless we are required to comply with a valid subpoena or court order.

We also encourage your patients to understand the extent of their legal protection under the federal Genetic Information Nondiscrimination Act (GINA), which protects against employer and health insurance company discrimination based on one’s genetics.

* The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. The relevance of each report varies based on ethnicity. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. Our carrier status reports can be used to determine carrier status, but cannot determine if an individual has two copies of any genetic variant. These carrier reports are not intended to tell an individual anything about risk for developing a disease in the future or anything about the health of a fetus, or newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to diagnose disease, determine medical treatment or medical intervention including whether to take a medication or how much of a medication to take, or tell the user anything about their current state of health. Any diagnostic or treatment decisions must be based on confirmatory prescription testing and/or other information that you determine to be appropriate for your patient, such as additional clinical testing and other risk factors that may affect individual risk and health care.